Webinar Information and Registration
Ask the Expert:
Strategies for Optimizing Antimicrobial Use in ABSSSI and CABP
Tuesday, March 25, 2014
1-2 pm EST
After registration, you will receive an e-mail confirmation with instructions for joining the webinar.
Accreditation for Pharmacists
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity provides 1 hour (0.1 CEU) of continuing pharmacy education credit (activity # 0204-0000-14-463-L01-P).
This activity is provided free of charge. Participants must participate in the entire presentation, submit an enrollment code (announced during the webinar), and complete the course evaluation to receive continuing pharmacy education (CPE) credit. Participants will process CPE credit online at http://elearning.ashp.org/my-activities, with the option of printing a CPE certificate. CPE credit will be reported directly to CPE Monitor. View full CE processing instructions.
Methods and Format
This is a live web-based activity consisting of audio, presentation slides, and an activity evaluation tool. A live webinar brings the presentation to you. Listen to the speaker present in “real time” as you watch the slides on the screen. You will have the opportunity to ask the speaker questions at the end of the program. Please join the conference at least 5 minutes before the scheduled start time for important announcements.
Target Audience
This continuing pharmacy education activity was planned to meet the needs of pharmacists in a variety of practice settings, including large and small health systems, ambulatory care clinics, managed care organizations, and academia. This activity would be particularly beneficial for pharmacists, clinical specialists, pharmacy managers, leaders, and educators who are interested in infectious diseases.
Webinar Overview
This activity will focus factors integral to optimizing use of antimicrobials for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). Evidence based guidelines and recommendations will be reviewed, and guidance for incorporating antimicrobial stewardship principles into decision making processes for selecting therapies for both empiric and targeted therapies will be emphasized. Particular emphasis will be placed on delineating the role of newer antibiotics that have gained FDA approval for ABSSSI and CABP since the most recent version of consensus treatment guidelines have been published.
Learning Objectives
After participating in this application-based educational activity, attendees should be able to
- Compare and contrast at least one new FDA approved agent to current guideline endorsed therapies for ABSSSI and for CABP.
- Choose a first-line therapy and an alternative therapy recommendation for ABSSSI and CABP that are suitable for an institutional clinical pathway.